New automated VPT systems for topical drug performance testing11 Jan 2018
The MedStat-HT and MedFlux-HT help to de-risk development programs and shorten development timelines.
MedPharm has launched two automated testing services, MedStat-HT and MedFlux-HT to de-risk clients' development programs and shorten development timelines. Both pieces of equipment incorporate design features that provide significant improvements over commercially available systems.
MedFlux-HT is an automated system of 32 flow-through diffusion cells for measuring the in vitro permeation and penetration of drugs into and through human skin (IVPT). It can also be set up with other tissues determined by the medicine’s target site (e.g., mucosal, buccal, etc.). The system has been uniquely designed to provide local clearance of the tissue to mimic the clinical setting and to maximise sink conditions without the addition of solvents when studying lipophilic compounds in static cells.
Another key design improvement is the use of a high-throughput collection enabling reduction in sample collection, set-up time, and processing which can be further coupled with liquid handlers and automated sample managers. MedPharm use MedFlux-HT® as a key tool in topical formulation development, and optimisation. Significant benefits of this new system include reduction in sample variation, system artefacts, and experimental time to further de-risk topical formulation development prior to clinical trials. The use of MedFlux-HT has been important in the support of patent claims, substantiation of marketing claims for OTC products, new chemical entity development, and development of generic products.
MedStat-HT is an automated system of 24 vertical diffusion cells (VDC) more commonly known as ‘Franz’ or ‘static’ cells for measuring the in vitro release of drug from topical medicines across synthetic membranes (IVRT). Unique design features along with automated collection provide significant reduction in variation associated with sampling and fluidics compared with manually operated VDC systems. The key benefits of the new system are its ability to better characterise formulation drug release properties for potential patent claim support (formulation optimisation and comparison, and potential product quality and stability specifications) with a reduction in experimental time and less variability.
"MedPharm is continuing to develop innovative solutions to help our clients further de-risk their topical development programs and reduce development timelines," commented Jon Lenn, MedPharm’s Vice President of US Operations. He added: "MedStat-HT and MedFlux-HT greatly improve the efficiency of data collection and decrease variations seen with conventional systems for IVRT and IVPT, so clients and their investors gain confidence in the data generated and ultimately get to the market sooner."
Natural lipid acts as potent anti-inflammatory
10 Jul 2018
Scientists see therapeutic potential against bacteria, viruses.Read more
Plasticell leads gene therapy manufacturing consortium
3 Jul 2018
Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.Read more
Follicum develops new direct-to-scalp formulation
27 Jun 2018
The topical treatment for hair loss boasts a 'commercial' formulation.Read more
Collaboration to provide GMP-based services
19 Jun 2018
Researchers to benefit by receiving a rapid and cost-effective scaled supply of new compounds.Read more
Locate Therapeutics secures £2 million to fast-track development of innovative cell therapy programs
5 Jun 2018
TAOS matrix system and products hailed as potential ‘game changers’ in the field of regenerative medicine.Read more
Anti-vedolizumab antibodies to support treatment research
25 May 2018
A reliable source of antibodies for the development of bioanalytical assays for vedolizumab, to support research into the treatment of ulcerative colitis and Crohn’s diseaseRead more
The shortest way from the lab to continuous production
24 May 2018
Bosch's new Xelum R&D for continuous production of oral solid dosage forms ensures a short time-to-market and optimum dosing of APIs.Read more
Comparative analysis of a complex monoclonal antibody
24 May 2018
New poster describes how the EAF4 module enabled simultaneous measurement of size and surface charge characteristics of antibodies and proteins.Read more
Lilly expands oncology pipeline with acquisition
16 May 2018
Acquisition of AurKa Pharma expands Lilly's oncology pipeline with early-phase asset being studied in multiple tumour types.Read more
Versatile lyophilizer for research, development or small-scale production
15 May 2018
Allows for easy and intuitive scale-up from research.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation